CDNA Stock CareDx, Inc.
Today’s call · CDNA
All live ideas →Checks are split 3–3 — no clear lean
CDNA is in an uptrend, momentum soft. $80 is the level overhead; $68.6 the first support below.
- A close above $80 on rising volume (breakout).
- A pullback to $68.6 that holds (entry near support).
The brief
All readings
Levels that matter
Compare with…
CareDx (CDNA) stock analysis, November 20, 2026: bullish on upside breakout
CareDx (CDNA) closed at $69.78 on November 20, 2026, still trading well above its 50‑day average of $68.6 and the 40‑week trend line. The daily trend is in step with a weekly uptrend, and the stock has been out‑performing the S&P 500 by more than 11 % over the past 50 days. The balance of evidence points to a bullish outlook for the next two to six weeks, with a clear upside breakout target near the 52‑week high of $88.47 and a risk‑reward profile that meets a 3‑to‑1 edge.
Why it matters
The recent price action reflects a market that has already priced in a substantial correction from the $88.47 peak recorded on November 3, 2026. The stock fell 21.1 % from that high, while the broader S&P 500 slipped 8.1 % over the same five‑day window. CDNA’s own five‑day decline of 10.4 % was larger than the sector health‑care ETF XLV’s 5.8 % drop, indicating that the move was driven more by stock‑specific factors than by sector weakness.
Despite the pullback, CDNA remains above its 40‑week average, a long‑term bullish signal that keeps the longer‑term thesis intact. The 50‑day simple moving average at $68.6 now acts as a support level; the price has held above it, and the first crack below that average would be a warning sign. The weekly trend remains upward, and the daily RSI of 43.7 suggests room for further upside before reaching overbought territory.
Analyst consensus remains a “Buy” with a mean price target of $94.43, implying a 26 % discount to that target at current levels. The spread between the low ($90) and high ($100) targets underscores a wide upside potential that is not yet reflected in the market price.
Debate around CDNA centers on whether the recent weakness is a temporary over‑reaction or a sign of deeper execution risk. One camp points to the stock’s out‑performance versus the S&P 500 (+11.5 % over 50 days) and its leadership over XLV (+1.3 % over 50 days) as evidence that the underlying business momentum remains strong. The opposing view highlights the steep 21 % drop from the 52‑week high and the 61 % volume decline relative to the 20‑day average, arguing that buying pressure has faded.
Even with the volume weakness, the breakout math remains intact: a daily close above the round $70 level on volume exceeding the 20‑day average would trigger the upside scenario. The stop is set at $67.34, derived from the 50‑day average less a quarter of the 14‑day ATR, giving a reward‑to‑risk ratio of 6.9 to the target at $88.47.
What the evidence says
On the long‑term horizon, the thesis that CDNA is positioned for growth in the diagnostics and research segment of healthcare remains solid. The stock stays above its 40‑week average, the 50‑day average is intact, and the market cap of $3.66 billion reflects a sizable, albeit volatile, position in a sector that has delivered a 14.9 % year‑to‑date gain for XLV. The recent correction has not altered the structural upside bias.
Looking ahead to the next two to six weeks, the balance of evidence leans strongly positive. The assessment calls for a bullish stance with high conviction, supported by three of four conviction points: daily trend alignment, out‑performance versus the S&P 500, and out‑performance versus XLV. The breakout criteria are clearly defined, and the math meets a 3‑to‑1 reward‑to‑risk threshold, reinforcing the high conviction rating.
The strongest counter‑argument is the 61.3 % drop in volume relative to the 20‑day average, which could signal waning buying interest. However, that weakness is offset by the price holding above the 50‑day average and the continued out‑performance metrics, keeping the conviction from slipping lower.
Levels that matter
The structure holds above the $68.6 SMA‑50, which is the nearest technical support. A break below that level would constitute the first crack and could shift the short‑term bias. The longer‑term trend would be considered ended if the price fell below the $38.04 SMA‑200, a level that would require a weekly close beneath it to trigger a trend change.
The breakout level is a daily close above $70 on volume above the 20‑day average. If that occurs, the math projects a target at the 52‑week high of $88.47, with a stop at $67.34. The reward‑to‑risk ratio of 6.9 to 1 comfortably exceeds the 3‑to‑1 threshold, making the upside scenario statistically attractive.
What would change the picture
A weekly close below the $38.04 SMA‑200 would rewrite the weekly trend and invalidate the current bullish outlook. The only non‑price catalyst that could produce such a close is a materially negative earnings surprise that forces a reassessment of the company’s growth prospects.
What to watch
- Next earnings release on October 29, 2026 – the earnings per share figure will be the key number to watch for any deviation from consensus expectations.
- Sector‑wide developments such as FDA approvals or policy changes affecting diagnostics, which could move CDNA before its own news.
- Analyst valuation spread: the mean price target of $94.43 implies a 26 % upside from the current price, highlighting a valuation gap that remains unfilled.